Cellectis (CLLS) and La Jolla Pharmaceutical (LJPC) Financial Contrast
Cellectis (NASDAQ: LJPC) and La Jolla Pharmaceutical (NASDAQ:LJPC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Valuation and Earnings
This table compares Cellectis and La Jolla Pharmaceutical’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellectis||$33.72 million||35.75||-$99.36 million||($2.78)||-10.42|
|La Jolla Pharmaceutical||$620,000.00||907.05||-$114.80 million||($5.41)||-3.96|
Volatility & Risk
Cellectis has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, La Jolla Pharmaceutical has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.
Institutional & Insider Ownership
27.1% of Cellectis shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 25.3% of La Jolla Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for Cellectis and La Jolla Pharmaceutical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|La Jolla Pharmaceutical||2||0||4||0||2.33|
Cellectis presently has a consensus target price of $46.80, indicating a potential upside of 61.49%. La Jolla Pharmaceutical has a consensus target price of $51.83, indicating a potential upside of 141.76%. Given La Jolla Pharmaceutical’s higher probable upside, analysts plainly believe La Jolla Pharmaceutical is more favorable than Cellectis.
This table compares Cellectis and La Jolla Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|La Jolla Pharmaceutical||N/A||-147.98%||-94.78%|
Cellectis beats La Jolla Pharmaceutical on 8 of the 12 factors compared between the two stocks.
Cellectis Company Profile
Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. The company is developing LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.